VivoSeq
Other

Long Term Efficacy and Safety

0

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Long Term Efficacy and Safety is an early-stage landscape with 0 programs across 2 companies. The most active players are Hansa Biopharma AB, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hansa Biopharma AB

1 program

Phase 3Novartis logo

Novartis

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed4 · 67%
Recruiting1 · 17%
Active, not recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia
Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05816343·28 enrolled
A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort
Active, not recruiting·HHansa Biopharma AB·Phase 3·NCT05937750·150 enrolled
Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
Completed·Novartis logoNovartis·Phase 3·NCT00239811·684 enrolled
The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients
Completed·VVericel Corporation·N/A·NCT00140634·2,233 enrolled
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
Completed·Novartis logoNovartis·Phase 4·NCT00434447·73 enrolled
To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)
Completed·—·Phase 3·NCT00150176·831 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)